Weight Loss Under research

Adipotide

Also known as: FTPP, Prohibitin-targeting peptide

Adipotide is an experimental peptidomimetic peptide designed to combat obesity in a radically different way than other drugs. Instead of suppressing appetite, it induces apoptosis (programmed cell death) in the blood vessels that feed white adipose tissue (fat). By depriving fat cells of blood, they die and are reabsorbed by the body.

Mechanism of action

Targets and binds specifically to a receptor on the surface of blood vessels supplying white adipose tissue (Prohibitin protein).
Once bound, it triggers an intracellular cascade causing the destruction of the blood vessel.
The fat tissue, deprived of blood flow, undergoes rapid apoptosis and is cleared by macrophages.

Uses & indications

Extreme fat reduction: In animal models it has completely reversed severe obesity.
Research use: As a potential alternative to chemical liposuction.

Effects

Profound and accelerated weight loss dependent on real fat reduction, not water or muscle. Rapid decrease in abdominal circumference in test subjects.

Considerations & contraindications

High renal (kidney) toxicity detected in primate studies. Lesions in renal tubules are reversible but concerning.
Not approved for humans; extremely potent and risky compound.

Regulatory approval

Halted in early clinical phases due to renal safety concerns.

Dosage

Data only from macaque trials; translation to human dose is purely experimental and dangerous.

Storage

Lyophilized at -20°C.

Technical data

Regulatory status Under research

Molecular weight 2555.22 Da

Half-life Corta, pero el efecto apoptótico es irreversible en el vaso

Administration routes Subcutánea